Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824462 | 0.88 | HRH3 (0.51) | HRH3HDAC1MAP4K4HRH1 | |
| SCHEMBL1743197 | 0.83 | HRH3 (0.46) | HRH3RETCNR2HDAC1DGAT1 | |
| SCHEMBL30191321 | 0.82 | HRH3 (0.49) | HRH3 | |
| SCHEMBL3387350 | 0.82 | HRH3 (0.49) | HRH3 | |
| SCHEMBL1742364 | 0.82 | HRH3 (0.52) | HRH3RETHDAC1PIK3CA | |
| SCHEMBL1744575 | 0.82 | DGAT1 (0.52) | HRH3DGAT1 | |
| SCHEMBL1743035 | 0.81 | HRH3 (0.59) | HRH3RETHDAC1PIK3CA | |
| SCHEMBL27687106 | 0.80 | HRH3 (0.51) | HRH3RETHDAC1PIK3CADGAT1 | |
| SCHEMBL27903434 | 0.80 | HRH3 (0.41) | HRH3RETCNR2HDAC1PIK3CA | |
| SCHEMBL1744672 | 0.80 | HRH3 (0.50) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7494995-B2 | Phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2009-02-24 | — | — | US | disclosed |
| WO-2006120348-A1 | NOVEL PHENYL-PYRIDINYL-PIPERAZINE DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | LES LABORATOIRES SERVIER (FR) | 2006-11-16 | — | — | WO | disclosed |
| US-20060258671-A1 | Phenylpyridylpiperazine compounds | LES LABORATORIES SERVIER (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1721896-A1 | Phenylpyridinylpiperazin derivatives, the process to make them and the compositions containing them | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258671-A1 | Phenylpyridylpiperazine compounds | HRH4, HRH3, HRH2 | HRH3 2/4885RET 386/4885CNR2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.